BioMed X, Roche Enter Immunology Research Pact

BioMed X has entered a new research collaboration with F. Hoffmann-La Roche in the field of immunology. BioMed X will launch a global call for applications to establish a new biomedical research group in Heidelberg. The goal the new group will be to develop novel approaches for the treatment of several immune-mediated diseases.

Roche is seeking to identify key checkpoints and master switches governing functional adaptation of myeloid cells, which are capable of diverse functions in the immune system, and to establish the functional consequences of these signals, and establish assay systems to monitor functional alterations. The goal is to harness myeloid cell plasticity to counteract pro-inflammatory differentiation and activation, and to restore homeostasis in immune-mediated diseases.

Successful candidates will be invited to a five-day boot camp to develop a research plan under guidance of experienced mentors. Final winners will be offered a two- to four-year fellowship to implement their research proposal at the BioMed X Innovation Center in Heidelberg.

"We are very proud to extend this collaboration now into the pharma division," said Christian Tidona, founder and managing director of BioMed X. "This is our third collaboration in the field of immunology which will further strengthen our expertise in this important area of research."

Register as Visitor to CPhI China 2018!